Skip to main content
NIH funding notice PAR-24-293

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Open. Closes August 18, 2027.

Posted
October 1, 2024
Close date
August 18, 2027
Activity codes
UG3, UH3
Institutes taking part
NINDS, NEI, NIA, NIAAA, NIDCR, NIDA, NIEHS, NIMH, NCCIH, OBSSR

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

  1. Reissues: PAR-21-163 Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

Who won it before

6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $5,520,510 in first-year total cost, median $721,581.

Most frequent study sections

  1. Special Emphasis Panel[ZNS1 SRB-Q (04)]2
  2. Neurological Sciences and Disorders B Study Section[NSD-B]1
  3. Special Emphasis Panel[ZNS1 SRB-Q (07)]1
  4. Special Emphasis Panel[ZNS1 SRB-Q (09)]1
  5. Special Emphasis Panel[ZNS1 SRB-Q (12)]1

Most frequent institutions

  1. NORTHWESTERN UNIVERSITY AT CHICAGO1
  2. RUTGERS BIOMEDICAL AND HEALTH SCIENCES1
  3. UNIV OF NORTH CAROLINA CHAPEL HILL1
  4. UNIVERSITY OF CALIFORNIA, SAN DIEGO1
  5. UNIVERSITY OF FLORIDA1
Competing awards under PAR-24-293 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Genome editor therapy for Angelman syndrome1UG3NS137515-01A1 · under PAR-21-163ZYLKA, MARK J.UNIV OF NORTH CAROLINA CHAPEL HILL, NC$1,508,248ZNS1
2024Cortical Interneuron Transplantation to Treat Intractable Epilepsy1UG3NS129630-01A1 · under PAR-21-163CHUNG, SANGMIRUTGERS BIOMEDICAL AND HEALTH SCIENCES, NJ$666,380ZNS1
2024Procession to IND of a capsid mutated AAV8 codon optimized NAGLU vector for treatment of Sanfilippo Syndrome type B1UG3NS137533-01 · under PAR-21-163BYRNE, BARRY JHELDERMON, COY DUNIVERSITY OF FLORIDA, FL$583,430ZNS1
2023Development of AAV-AIBP for neuroprotection in glaucoma1UG3NS129684-01A1 · under PAR-21-163JU, WONKYUUNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$776,782ZNS1
2023Development of Utrophin Site Blocking Oligos (SBOs) to Treat Duchenne Muscular Dystrophy (DMD)1UG3NS132420-01 · under PAR-21-163KHURANA, TEJVIR SUNIVERSITY OF PENNSYLVANIA, PA$490,761ZNS1
2022Development of anti-LTBP4 as a biologic to treat Neuromuscular Diseases1UG3NS127383-01 · under PAR-21-163DEMONBREUN, ALEXIS R.MCNALLY, ELIZABETH MNORTHWESTERN UNIVERSITY AT CHICAGO, IL$1,494,909NSD

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-24-293: Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) | ScienceDex | ConductScience